4-(4-methyl-2,5-dioxoimidazolidin-4-yl)benzonitrile | 169808-00-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑烷类
• 英文名称: 4-(4-methyl-2,5-dioxoimidazolidin-4-yl)benzonitrile
• CAS: 169808-00-8
• 化学式: C₁₁H₉N₃O₂
• mdl: MFCD01937525
• 分子量: 215.211
• InChiKey: NBPPTCRAKRHCOX-UHFFFAOYSA-N

物化性质

• 熔点：
  203-205 °C(Solv: ethanol (64-17-5))
• 密度：
  1.37±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  16
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.181
• 拓扑面积：
  82
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-(4-methyl-2,5-dioxoimidazolidin-4-yl)benzonitrile 在 10percent Pd/C 盐酸 、 sodium hydroxide 、 氢气 、 sodium methylate 、 溶剂黄146 作用下， 以 1,4-二氧六环 、 甲醇 、 乙醇 为溶剂， 20.0~100.0 ℃ 、300.01 kPa 条件下， 反应 19.0h， 生成 2-[4-(R,S)-(4-tert-butoxycarbonylaminomethyl-phenyl)-4-methyl-2,5-dioxoimidazolidin-1-yl]acetic acid
  参考文献：
  名称：

  基于乙内酰脲支架的口服活性非肽纤维蛋白原受体拮抗剂的发现。

  摘要：

  血小板纤维蛋白原受体（GP IIb / IIIa受体）的拮抗剂有望成为一种有前途的新型抗血栓药。纤维蛋白原与纤维蛋白原受体的结合取决于Arg-Gly-Asp-Ser（RGDS）四肽识别基序。RGDS导联的结构修饰导致发现了非肽RGD模拟GP IIb / IIIa拮抗剂44（S 1197）。化合物44以剂量依赖和可逆的方式抑制人和狗的血小板聚集以及125I-纤维蛋白原与ADP激活的人凝胶过滤的血小板和分离的GP IIb / IIIa的结合，K（i）的K（i）值为9 nM和0.17 nM ， 分别。使用QXP进行药效团映射的程序以及应用GRID / GOLPE方法进行的3D-QSAR分析产生了稳定的，相当可预测的模型，并揭示了对绑定非常重要的结构特征。在乙内酰脲核和C-末端的疏水取代均增加了对血纤蛋白原受体的亲和力。结晶乙酯前药48（HMR 1794）是一种口服活性抗血栓药，是治疗人类血栓性疾病的有前途的候选药物。

  DOI：

  10.1021/jm001068s
• 作为产物：
  描述：

  对氰基苯乙酮 在 ammonium carbonate 作用下， 以 正丙醇水 、 水 为溶剂， 生成 4-(4-methyl-2,5-dioxoimidazolidin-4-yl)benzonitrile
  参考文献：
  名称：

  Process for the preparation of chiral, nonracemic

  摘要：

  本发明涉及一种制备手性、非拉克米化合物的方法，其化学式为I，在该化学式中，R.sup.1和R.sup.2具有权利要求书中指示的含义，并且它们是用于制备药用活性化合物的有用中间体，其中，为了分离，从化学式I的拉克米化合物和手性、非拉克米氨基化合物形成盐。此外，本发明还涉及化学式I及其酯化合物。

  公开号：

  US06018053A1

文献信息

• Substituted 5-membered ring heterocycles, their preparation and their use
  申请人：Hoechst Aktiengesellschaft

  公开号：US05981492A1

  公开（公告）日：1999-11-09

  The present invention pertains to 5-ring heterocycles of general formula (I), wherein W, Y, Z, B, D, E and R as well as b, c, d, e, f, g, and h are as indicated in the description; to methods for preparing them, and to their use as inhibitors of platelet aggregation, metastasizing of carcinomatous cells and the attachment of osteoclasts to the bone surface. ##STR1##

  本发明涉及一般式（I）的5-环杂环化合物，其中W、Y、Z、B、D、E和R以及b、c、d、e、f、g和h如描述中所示；以及其制备方法，以及它们作为抑制血小板聚集、癌细胞转移和破骨细胞附着于骨表面的用途。
• Heterocyclic compounds, their preparation and their use as leucocyte
  申请人：Hoechst Marion Roussel Deutschland GmbH

  公开号：US06034238A1

  公开（公告）日：2000-03-07

  Compounds of the formula I, ##STR1## in which B, E, W, Y, Z, R, R.sup.2, R.sup.2a, R.sup.2b, R.sup.3, g and h have the meanings indicated in the specifications. The compounds of the formula I are valuable pharmaceutical active compounds, which are suitable, for example, for the therapy and prophylaxis of inflammatory disorders, for example of rheumatoid arthritis, or of allergic disorders. The compounds of the formula I are inhibitors of the adhesion and migration of leucocytes and/or antagonists of the adhesion receptor VLA-4 belonging to the integrins group. They are generally suitable for the therapy or prophylaxis of illnesses which are caused by an undesired extent of leucocyte adhesion and/or leucocyte migration or are associated therewith, or in which cell-cell or cell-matrix interactions which are based on interactions of VLA-4 receptors with their ligands play a part. The invention furthermore relates to processes for the preparation of the compounds of the formula I, their use in the therapy and prophylaxis of the disease states mentioned and pharmaceutical preparations which contain the compounds of the formula I.

  公式I的化合物，##STR1##其中B、E、W、Y、Z、R、R.sup.2、R.sup.2a、R.sup.2b、R.sup.3、g和h在规范中有所指示的含义。公式I的化合物是有价值的药用活性化合物，例如适用于炎症性疾病的治疗和预防，例如类风湿性关节炎或过敏性疾病。公式I的化合物是白细胞粘附和迁移的抑制剂和/或整合素群中属于VLA-4粘附受体的拮抗剂。它们通常适用于由于白细胞粘附和/或白细胞迁移的不良程度引起的疾病的治疗或预防，或与之相关的疾病，或者在其中基于VLA-4受体与其配体相互作用的细胞-细胞或细胞-基质相互作用起作用。此外，本发明还涉及制备公式I的化合物的方法，它们在治疗和预防所述疾病状态中的使用以及含有公式I的药物制剂。
• Novel heterocycles as inhibitors of leucocyte adhesion and as VLA-4 antagonists
  申请人：——

  公开号：US20020065391A1

  公开（公告）日：2002-05-30

  The present invention relates to compounds of the formula I 1 which are inhibitors of the adhesion and migration of leucocytes and/or antagonists of the adhesion receptor VLA-4 which belongs to the group of integrins. The invention also relates to processes for their preparation, to the use of compounds of the formula I for the treatment or prophylaxis of diseases which are caused by an undesired extent of leucocyte adhesion and/or leucocyte migration or which are associated therewith or in which cell-cell or cell-matrix interactions which are based on interactions of VLA-4 receptors with their ligands play a part, for example of inflammatory processes, of rheumatoid arthritis or of allergic disorders, and also to the use of compounds of the formula I for the production of pharmaceuticals for use in such diseases, and to pharmaceutical preparations which contain the compounds of the formula I.

  本发明涉及式I的化合物，该化合物是白细胞粘附和迁移的抑制剂和/或属于整合素群的粘附受体VLA-4的拮抗剂。该发明还涉及它们的制备方法，化合物式I用于治疗或预防由于白细胞粘附和/或白细胞迁移的不良程度引起的疾病，或与之相关的疾病，或基于VLA-4受体与其配体相互作用而发挥作用的细胞-细胞或细胞-基质相互作用的疾病，例如炎症过程、类风湿关节炎或过敏性疾病，以及化合物式I用于生产用于此类疾病的药物，以及含有化合物式I的药物制剂。
• 5-Membered ring heterocycles as inhibitors of leucocyte adhesion and as VLA-4 antagonists
  申请人：Aventis Pharma Deutschland GmbH

  公开号：US20040220148A1

  公开（公告）日：2004-11-04

  Compounds of the formula I 1 in which B, D, E, R, W, Y, Z, b, c, d, e, f, g and h have the meanings indicated in the claims, are inhibitors of the adhesion and migration of leucocytes and/or antagonists of the adhesion receptor VLA-4 which belongs to the group of integrins. The invention relates to the use of compounds of the formula I and of pharmaceutical preparations which contain such compounds for the treatment and prophylaxis of diseases which are caused by an undesired extent of leucocyte adhesion and/or leucocyte migration or which are associated therewith or in which cell-cell or cell-matrix interactions which are based on interactions of VLA-4 receptors with their ligands play a part, for example of inflammatory processes, of rheumatoid arthritis or of allergic disorders, and it also relates to the use of compounds of the formula I for the production of pharmaceuticals for use in such diseases. It further relates to novel compounds of the formula I.

  公式I中B、D、E、R、W、Y、Z、b、c、d、e、f、g和h具有索引中指示的含义，是白细胞粘附和迁移的抑制剂和/或属于整合素群的粘附受体VLA-4的拮抗剂。本发明涉及公式I化合物的使用以及含有这种化合物的药物制剂，用于治疗和预防由白细胞粘附和/或白细胞迁移的不良程度引起的疾病，或与之相关的疾病，或基于VLA-4受体与其配体相互作用的细胞-细胞或细胞-基质相互作用在其中起作用的炎症过程、类风湿关节炎或过敏性疾病等，还涉及公式I化合物用于生产用于治疗此类疾病的药物。此外，还涉及公式I的新化合物。
• Hydantoin compounds, salts thereof, processes for their preparation, and
  申请人：Hoechst Aktiengesellschaft

  公开号：US05939556A1

  公开（公告）日：1999-08-17

  The present invention relates to hydantoin derivatives of the formula I ##STR1## and which are intermediates for the preparation of pharmaceutical active compounds, their preparation and their use in the preparation of the active compounds.

  本发明涉及公式I的咪唑烷二酮衍生物，它们是制备药用活性化合物的中间体，以及它们的制备和在活性化合物的制备中的使用。